EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access

Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non–Small Cell Lung Cancer

Wentao Fang, Yiyang Wang, Wenxiang Wang, Lin Wu, Longhua Sun, Peng Zhang, Shun Lu, Neotorch Investigators, Yan Zheng, Qixun Chen, Lijie Tan, Lin Yang und 48 weitere

JAMA Surgery · 01.09.2026 · 161 (9) · 881

DOI: 10.1001/jamasurg.2026.2711 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Surgery, erschienen am 01.09.2026. Verfasst von Wentao Fang und 59 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Perioperative immunotherapy has improved clinical outcomes for patients with early-stage non–small cell lung cancer (NSCLC). The influence of immune checkpoint inhibitor in combination with chemotherapy on surgical outcomes remains to be explored.

Objective

To evaluate perioperative toripalimab in combination with chemotherapy on surgical outcomes. Design, Setting, and Participants This multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial (Neotorch study) enrolled patients with resectable stage III NSCLC and took place at 50 centers in China. Patients who had histologically confirmed resectable stage IIIA or IIIB NSCLC were eligible. These data were analyzed from July 2024 to March 2026.

Interventions

Patients were randomized (1:1) to receive toripalimab (240 mg) plus platinum-based chemotherapy or placebo plus platinum-based chemotherapy for 3 cycles before surgery and 1 cycle after surgery, followed by maintenance with toripalimab or placebo alone for 13 cycles. Main Outcomes and Measures Surgical outcomes, including perioperative complications, tumor downstaging, and lymph node downstaging, and their association with event-free survival (EFS), were studied in this post hoc analysis.

Results

Among 404 patients enrolled, 314 patients (median [SD] age 60 [6.82] years; 90% of patients were male and 10% were female) underwent surgery (166 in toripalimab group and 148 in placebo group). Percentage of patients canceling surgery (17.8% vs 26.7%; P = .03) was significantly lower in the toripalimab group. Proportions of minimally invasive surgery, R0 resection, and lobectomy were slightly higher in the toripalimab group. Surgical complications were similar between the 2 groups. Rates of postsurgery tumor (80.7% vs 50.7%; P < .001) and lymph node downstaging (67.5% vs 48.6%; P = .001) were both significantly higher with toripalimab than placebo. With a median follow-up of 18.3 months, a better EFS was noticed in the toripalimab group. Tumor and lymph node downstaging in the toripalimab group were both associated with better EFS than nondownstaging (median EFS, not estimable [NE] vs 17.5 months; P = .004 and NE vs 19.2 months; P = .001, respectively), and were also associated with even better EFS than tumor and lymph node downstaging in the placebo group (median EFS, NE vs 22.0 months; P = .002 and NE vs NE; P = .009, respectively). Conclusions and Relevance In this study, perioperative toripalimab plus chemotherapy showed comparable perioperative outcomes, as with chemotherapy alone without new safety signals, and could help improve survival through effective tumor downstaging in patients with resectable stage III NSCLC. Trial Registration ClinicalTrials. gov Identifier: NCT04158440

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsHumansFemaleMaleNeoplasm StagingDouble-Blind MethodMiddle AgedPneumonectomyAgedPerioperative CareAntineoplastic Combined Chemotherapy ProtocolsTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China.
  • The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Shanghai Pulmonary Hospital, Tong Ji University, Shanghai, China.
  • Henan Cancer Hospital, Zhengzhou, China.
  • Zhejiang Cancer Hospital, Hangzhou, China.

Zitieren

APA

Fang, W., Wang, Y., Wang, W., Wu, L., Sun, L., Zhang, P., Lu, S., Neotorch Investigators, Zheng, Y., Chen, Q., Tan, L., Yang, L., Mei, J., Sun, X., Xu, S., Shan, J., Yang, N., Yu, D., Chen, Y., …, & Chen, G. (2026). Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non–Small Cell Lung Cancer. JAMA Surgery, 161(9), 881. https://doi.org/10.1001/jamasurg.2026.2711

Vancouver

Fang W, Wang Y, Wang W, Wu L, Sun L, Zhang P, et al. Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non–Small Cell Lung Cancer. JAMA Surgery. 2026;161(9):881. doi:10.1001/jamasurg.2026.2711

BibTeX
@article{Fang2026,
  author = {Fang, Wentao and Wang, Yiyang and Wang, Wenxiang and Wu, Lin and Sun, Longhua and Zhang, Peng and Lu, Shun and Neotorch Investigators, Neotorch Investigators and Zheng, Yan and Chen, Qixun and Tan, Lijie and Yang, Lin and Mei, Jiandong and Sun, Xiaohong and Xu, Shidong and Shan, Jinlu and Yang, Nong and Yu, Dongliang and Chen, Yuping and Yu, Guohua and Hu, Xiaohua and Xing, Ligang and Wu, Nan and Chen, Keneng and Tian, Hui and Zhang, Xun and Liu, Yunpeng and Zhou, Ming and Fang, Haohui and Li, Shanqing and Ye, Minhua and Wu, Guowu and Cao, Lejie and Jiang, Jie and Zhu, Kunshou and Kang, Mingqiang and Xu, Haipeng and Li, Xingya and Zhu, Liangming and Zhong, Aihong and Sun, Qian and Wang, Changli and Ma, Haitao and Cai, Kaican and Zhang, Yu and Zhang, Xiaochun and Hu, Hong and Chen, Jun and Yang, Zhixiong and Hang, Xiaosheng and Zhang, Wengang and Huang, Yunchao and Hu, Jian and Zhang, Liwei and Yao, Jian and Zhang, Zhiye and Liu, Lunxu and Lin, Dongmei and Zhang, Jie and Chen, Gang},
  title = {Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non–Small Cell Lung Cancer},
  journal = {JAMA Surgery},
  year = {2026},
  volume = {161},
  number = {9},
  pages = {881},
  doi = {10.1001/jamasurg.2026.2711}
}
Kostenlos starten →